Cost-Effectiveness of Routine Screening for Critical Congenital Heart Disease in US Newborns
Cora Peterson(National Center on Birth Defects and Developmental Disabilities), Cynthia H. Cassell(Centers for Disease Control and Prevention), Matthew E. Oster(Children's Healthcare of Atlanta), Scott D. Grosse(National Center for Environmental Health), Richard S. Olney(University of Iowa)
Cited by 109
Related Papers
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
|JAMA|2022|670
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Guidelines for case classification for the national birth defects prevention study
|Birth Defects Research Part A Clinical and Molecular Teratology|2003|582
Sickle Hemoglobin (Hb S) Allele and Sickle Cell Disease: A HuGE Review
|American Journal of Epidemiology|2000|535
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
|New England Journal of Medicine|2007|501